IRINOTECAN Safety Questions, IRINOTECAN Answers
More Here>>Side Effects - FDA Reports 2006-2008
Medications A-Z: A B C D E F G H I J K L M N O P Q R S T U V W X Y ZWelcome! Patientsville.com provides unique information about IRINOTECAN. Our extensive database of IRINOTECAN adverse events and IRINOTECAN warnings is updated regularly. If you have questions, you can post them to one of our health experts or ask others in our broad patient community.
>> Announcements
Check out our Hospital and Home Care Quality Reports.
Ask Our Health Experts about IRINOTECAN
IRINOTECAN Safety Reports
Total IRINOTECAN reports: 266.IRINOTECAN FDA safety alerts: 2002 .
Reported deaths: 67 Reported hospitalizations: 169.
Take IRINOTECAN Side Effects Survey or Share Your IRINOTECAN Story. Read More Here.
Showing 1-75 of 266 Next >
Physician from KOREA, REPUBLIC OF reported IRINOTECAN problem on June 29, 2006. Male patient, 52 years of age, was diagnosed with gastric cancer and was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: abdominal pain upper, anaemia, diarrhoea, febrile neutropenia, lymphadenopathy, malignant neoplasm progression, neuropathy peripheral, pneumonia streptococcal. IRINOTECAN dosage: unknown. During the same period patient was treated with CISPLATIN, MESNA, ETOPOSIDE, PACLITAXEL. Patient was hospitalized. Patient died on 08/01/2004.IRINOTECAN problem was reported by a Consumer or non-health professional from JAPAN on July 04, 2006. Male patient was diagnosed with lung neoplasm malignant and was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: angina pectoris, bradycardia. IRINOTECAN dosage: unknown. Patient was hospitalized. Patient recovered.
Physician from SWITZERLAND reported IRINOTECAN problem on July 04, 2006. Male patient, 55 years of age, weighting 198.4 lb, was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: disease progression, myalgia, peripheral sensory neuropathy. IRINOTECAN dosage: 160 MG (FREQUENCY: CYCLIC), INTRAVENOUS. During the same period patient was treated with PLATIBLASTIN S, PLATIBLASTIN S, VIOXX. Patient recovered.
IRINOTECAN problem was reported by a Consumer or non-health professional from UNITED STATES on July 17, 2006. Male patient, weighting 233.7 lb, was diagnosed with glioblastoma multiforme and was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: asthenia, blood test abnormal, convulsion, disease progression, fatigue, investigation abnormal, somnolence. IRINOTECAN dosage: 125MG/M2 DAY 1, 8, 22, 29 IV. During the same period patient was treated with TEMODAR, WELLBUTRIN, DECADRON, PROVIGIL, XANAX, PROTONIX. Patient was hospitalized. Patient recovered.
Physician from JAPAN reported IRINOTECAN problem on June 30, 2006. Male patient, 78 years of age, weighting 131.0 lb, was diagnosed with lung neoplasm malignant and was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: chills, electrocardiogram qrs complex prolonged, flushing, heart rate increased, hypoxia, interstitial lung disease, loss of consciousness, respiratory arrest, shock. IRINOTECAN dosage: 95 MG, INTRAVENOUS. During the same period patient was treated with DECADRON, KYTRIL. Patient died on 06/29/2006.
IRINOTECAN problem was reported by a Physician from JAPAN on July 03, 2006. Male patient, 80 years of age, weighting 110.2 lb, was diagnosed with colon cancer and was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: diarrhoea, interstitial lung disease, leukopenia, pyrexia, vomiting. IRINOTECAN dosage: 100 MG/M2 (INTERMITTENT (100 MG)), INTRAVENOUS. Patient was hospitalized. Patient recovered.
Health Professional from FRANCE reported IRINOTECAN problem on July 06, 2006. Female patient, 73 years of age, was diagnosed with pancreatic carcinoma and was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: haemolytic anaemia. IRINOTECAN dosage: 180 MG/M*2 (DAILY), INTRAVENOUS. During the same period patient was treated with FLUOROURACIL, OXALIPLATIN, METHYLPREDNISOLONE SUCCINATE, ATROPINE. Patient was hospitalized. Patient recovered.
IRINOTECAN problem was reported by a Physician from JAPAN on July 04, 2006. Male patient, 82 years of age, was diagnosed with colon cancer, metastases to bone, metastases to liver, metastases to lung and was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: candidiasis, catheter related infection, emphysema, interstitial lung disease, lymphangiosis carcinomatosa, malignant neoplasm progression, metastases to bone, metastasis, multi-organ failure. IRINOTECAN dosage: (100 MG, D1 AND D15, CYCLIC), INTRAVENOUS. During the same period patient was treated with MITOMYCIN, PIPERACILLIN. Patient died on 03/04/2003.
Pharmacist from UNITED KINGDOM reported IRINOTECAN problem on July 11, 2006. Female patient, 40 years of age, was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: abdominal pain, dizziness, dyspnoea, throat tightness. IRINOTECAN dosage: unknown. During the same period patient was treated with ATROPINE. Patient was hospitalized. Patient recovered.
IRINOTECAN problem was reported by a Consumer or non-health professional from UNITED STATES on July 27, 2006. Female patient, weighting 114.6 lb, was diagnosed with oesophageal carcinoma and was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: dehydration, incontinence, leukopenia, nausea, pyrexia. IRINOTECAN dosage: unknown. During the same period patient was treated with CISPLATIN, CETUXIMAB, MIRALAX, FOSAMAX, ATIVAN, CLINDAGEL, CLONAZEPAM. Patient was hospitalized. Patient recovered.
Physician from JAPAN reported IRINOTECAN problem on May 11, 2006. Male patient, 80 years of age, was diagnosed with colon cancer and was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: cancer pain, constipation, dizziness, insomnia, status epilepticus, vomiting. IRINOTECAN dosage: 150 MG/BODY (150 MG, 1 IN 2 WK), INTRAVENOUS. During the same period patient was treated with FLUOROURACIL, CALCIUM LEVOFOLINATE. Patient recovered.
IRINOTECAN problem was reported by a Physician from JAPAN on July 20, 2006. Female patient, 82 years of age, weighting 72.75 lb, was diagnosed with ovarian cancer and was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: anorexia, interstitial lung disease, leukopenia, lung infection, lymphangiosis carcinomatosa, malaise, malignant ascites, malignant neoplasm progression, pyrexia. IRINOTECAN dosage: 25 MG (1 IN 1 WK), INTRAVENOUS. During the same period patient was treated with LANSOPRAZOLE, JUZENTAIHOTO, ALLOID, FLUCALIN. Patient was hospitalized. Patient recovered.
Consumer or non-health professional from SPAIN reported IRINOTECAN problem on Feb 09, 2005. Female patient, 73 years of age, was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: acute pulmonary oedema, granulocytopenia, pulmonary embolism. IRINOTECAN dosage: 338 MG DAILY IV. During the same period patient was treated with FOLINIC ACID, FLUOROURACIL. Patient was hospitalized. Patient recovered.
IRINOTECAN problem was reported by a Physician from IRELAND on July 25, 2006. Male patient, 70 years of age, was diagnosed with gastrointestinal carcinoma and was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: pulmonary fibrosis. IRINOTECAN dosage: 300 MG (300 MG, 1 IN 1 D). Patient recovered.
Physician from JAPAN reported IRINOTECAN problem on July 24, 2006. Male patient, 48 years of age, weighting 165.3 lb, was diagnosed with non-small cell lung cancer and was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: acute respiratory distress syndrome, blood ph increased, bone marrow failure, cold sweat, diarrhoea, infection, interstitial lung disease, lung disorder, malignant pleural effusion. IRINOTECAN dosage: 115 MG/M2 (115 MG, 1 IN 1 WK), INTRAVENOUS. During the same period patient was treated with NEUTROGIN, CISPLATIN, INSULIN, BROCIN, MORPHINE SULPHATE. Patient was hospitalized. Patient died on 05/25/2006.
IRINOTECAN problem was reported by a Physician from JAPAN on July 26, 2006. Male patient, 73 years of age, was diagnosed with hepatic neoplasm malignant and was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: acquired diaphragmatic eventration, anaemia, atelectasis, disease progression, hepatic failure, interstitial lung disease. IRINOTECAN dosage: unknown. During the same period patient was treated with FURTULON, URSO, GLYCYRON, DILTIAZEM HYDROCHLORIDE, NEUQUINON, ALDACTONE, LASIX. Patient recovered.
Health Professional from JAPAN reported IRINOTECAN problem on July 31, 2006. Female patient, 71 years of age, was diagnosed with ovarian cancer and was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: myelodysplastic syndrome. IRINOTECAN dosage: unknown. Patient recovered.
IRINOTECAN problem was reported by a Physician from JAPAN on July 24, 2006. Male patient, 48 years of age, weighting 165.3 lb, was diagnosed with non-small cell lung cancer and was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: acute respiratory distress syndrome, ascites, atelectasis, base excess increased, blood bicarbonate increased, blood ph increased, bone marrow failure, c-reactive protein increased, cold sweat. IRINOTECAN dosage: 115 MG/BODY (1 IN 1 WK), INTRAVENOUS. During the same period patient was treated with NEUTROGIN, CISPLATIN, INSULIN, BROCIN, MORPHINE SULPHATE. Patient was hospitalized. Patient died on 05/25/2006.
Physician from UNITED STATES reported IRINOTECAN problem on Aug 10, 2006. Male patient, 53 years of age, weighting 167.0 lb, was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: respiratory distress. IRINOTECAN dosage: 150 MG/M2 (1 IN 3 WK), INTRAVENOUS. During the same period patient was treated with OXALIPLATIN, NEULASTA, DEXAMETHASONE, ONDANSETRON, LORTAB, PROMETHAZINE. Patient died on 06/28/2006.
IRINOTECAN problem was reported by a Physician from KOREA, REPUBLIC OF on Aug 04, 2006. Male patient, 52 years of age, was diagnosed with gastric cancer and was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: anaemia, ascites, diarrhoea, febrile neutropenia, gastric cancer, lymphadenopathy, malignant neoplasm progression, metastases to liver, neuropathy peripheral. IRINOTECAN dosage: unknown. During the same period patient was treated with CISPLATIN, MESNA, ETOPOSIDE, PACLITAXEL. Patient was hospitalized. Patient died on 08/01/2004.
Physician from JAPAN reported IRINOTECAN problem on Aug 02, 2006. Male patient, 61 years of age, weighting 171.3 lb, was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: angina pectoris, bradyarrhythmia, electrocardiogram st segment elevation, prinzmetal angina. IRINOTECAN dosage: 100 MG (INTERMITTENT), INTRAVENOUS. During the same period patient was treated with PLATOSIN, CODEINE PHOSPHATE, HANGE, SOLITA, NASEA, HEPARIN, MANNIGEN, SEISHOKU. Patient was hospitalized. Patient recovered.
IRINOTECAN problem was reported by a Health Professional from JAPAN on Aug 04, 2006. Male patient, 67 years of age, weighting 131.8 lb, was diagnosed with gastric cancer and was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: abasia, blood pressure systolic decreased, decreased appetite, dehydration, depressed level of consciousness, ectopic antidiuretic hormone secretion, inappropriate antidiuretic hormone secretion, swelling, tri-iodothyronine free decreased. IRINOTECAN dosage: 140 MG, INTRAVENOUS. During the same period patient was treated with TEGAFUR, AMLODIPINE, ENALAPRIL MALEATE, LANSOPRAZOLE, LASIX, ALDACTONE, AMARYL, PURSENNID. Patient was hospitalized. Patient recovered.
Physician from IRELAND reported IRINOTECAN problem on Aug 08, 2006. Male patient, 70 years of age, weighting 123.5 lb, was diagnosed with colorectal cancer metastatic, metastases to lung and was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: emphysema, mucosal inflammation, pulmonary fibrosis. IRINOTECAN dosage: 300 MG (125 MG/M2, FREQUENCY: ONCE INTERVAL: EVERY 2 WEE). During the same period patient was treated with IRINOTECAN HYDROCHLORIDE SOLUTION, FLUOROURACIL, AVASTIN. Patient was hospitalized and became disabled. Patient recovered.
IRINOTECAN problem was reported by a Physician from FRANCE on Aug 09, 2006. Male patient, 64 years of age, was diagnosed with rectal cancer metastatic and was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: disease progression, infection, paronychia, skin chapped. IRINOTECAN dosage: unknown. During the same period patient was treated with CAPECITABINE. Patient recovered.
Physician from JAPAN reported IRINOTECAN problem on Aug 08, 2006. Female patient, 70 years of age, was diagnosed with ovarian cancer and was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: dizziness postural, hypokalaemia, incontinence, loss of consciousness. IRINOTECAN dosage: 100 MG/M2 (CYCLIC), INTRAVENOUS - MIDDLE OF JULY. Patient was hospitalized. Patient recovered.
IRINOTECAN problem was reported by a Health Professional from UNITED STATES on Aug 25, 2006. Male patient, 69 years of age, weighting 141.0 lb, was diagnosed with neoplasm malignant and was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: pneumonia. IRINOTECAN dosage: 50 MG/M2 D1,8,22,29 Q 6 WKS IV. During the same period patient was treated with CISPLATIN. Patient was hospitalized. Patient recovered.
Physician from UNITED STATES reported IRINOTECAN problem on Aug 10, 2006. Male patient, 53 years of age, weighting 167.0 lb, was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: acute respiratory distress syndrome. IRINOTECAN dosage: 150 MG/M2 (1 IN 3 WK), INTRAVENOUS. During the same period patient was treated with OXALIPLATIN, NEULASTA, DEXAMETHASONE, ONDANSETRON, LORTAB, PROMETHAZINE. Patient died on 06/28/2006.
IRINOTECAN problem was reported by a Health Professional from JAPAN on Aug 08, 2006. Female patient, 71 years of age, was diagnosed with ovarian cancer and was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: myelodysplastic syndrome. IRINOTECAN dosage: unknown. Patient recovered.
Consumer or non-health professional from UNITED STATES reported IRINOTECAN problem on Aug 29, 2006. Male patient, weighting 227.1 lb, was diagnosed with glioblastoma multiforme and was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: diplopia, headache, hydrocephalus, implant site haemorrhage, nausea, vith nerve paralysis, vomiting. IRINOTECAN dosage: 125MG/M2 DAY 1, 8, 22, 29 IV. During the same period patient was treated with TEMODAR, LOTREL, NEXIUM, DECADRON, GLUCOTROL, CALCIUM PLUS, VITAMIN D, ZOFRAN. Patient was hospitalized. Patient recovered.
IRINOTECAN problem was reported by a Consumer or non-health professional from UNITED STATES on Aug 29, 2006. Female patient, weighting 127.2 lb, was diagnosed with glioblastoma multiforme and was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: pneumothorax, procedural complication. IRINOTECAN dosage: 125MG/M2 DAY 1, 8, 22, 29 IV. During the same period patient was treated with TEMODAR. Patient was hospitalized. Patient recovered.
Health Professional from UNITED STATES reported IRINOTECAN problem on Aug 30, 2006. Female patient, weighting 114.6 lb, was diagnosed with oesophageal carcinoma and was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: anorexia, asthenia, dehydration, fatigue, incontinence, leukopenia, malnutrition, nausea, neutrophil count abnormal. IRINOTECAN dosage: unknown. During the same period patient was treated with CISPLATIN, CETUXIMAB, MIRALAX, FOSAMAX, ATIVAN, CLINDAGEL, CLONAZEPAM. Patient was hospitalized. Patient recovered.
IRINOTECAN problem was reported by a Physician from JAPAN on June 30, 2006. Male patient, 78 years of age, weighting 131.0 lb, was diagnosed with lung neoplasm malignant and was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: electrocardiogram qrs complex prolonged, flushing, heart rate increased, hypoxia, infection, interstitial lung disease, leukopenia, loss of consciousness, lymphangiosis carcinomatosa. IRINOTECAN dosage: 95 MG (INTERMITTENT), INTRAVENOUS. During the same period patient was treated with DECADRON, KYTRIL. Patient died on 06/29/2006.
Physician from JAPAN reported IRINOTECAN problem on Aug 11, 2006. Female patient, 70 years of age, weighting 89.29 lb, was diagnosed with ovarian cancer and was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: blood pressure decreased, heart rate abnormal, hypokalaemia, loss of consciousness, syncope vasovagal, urinary incontinence. IRINOTECAN dosage: unknown. During the same period patient was treated with NORVASC. Patient was hospitalized. Patient recovered.
IRINOTECAN problem was reported by a Consumer or non-health professional from UNITED STATES on Oct 12, 2005. Male patient, 47 years of age, was diagnosed with colon cancer and was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: carcinoembryonic antigen increased, thrombosis, weight increased. IRINOTECAN dosage: unknown. During the same period patient was treated with LEUCOVORIN ACID, FLUOROURACIL. Patient recovered.
Consumer or non-health professional from UNITED STATES reported IRINOTECAN problem on Sept 01, 2006. Male patient, weighting 227.1 lb, was diagnosed with glioblastoma multiforme and was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: csf pressure increased, diplopia, headache, hydrocephalus, nausea, post procedural haemorrhage, vith nerve paralysis, vomiting. IRINOTECAN dosage: 125MG/M2 DAY 1, 8, 22, 29 IV. During the same period patient was treated with TEMODAR, LOTREL, NEXIUM, DECADRON, GLUCOTROL, CALCIUM PLUS VITAMIN D, ZOFRAN, INNOHEP. Patient was hospitalized. Patient recovered.
IRINOTECAN problem was reported by a Physician from JAPAN on Aug 09, 2006. Male patient, 67 years of age, was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: interstitial lung disease. IRINOTECAN dosage: 171 MG, SINGLE. During the same period patient was treated with ZOFRAN, DECADRON, PRIMPERAN, CLONAZEPAM, MUCOSTA, DEPAS, MAGNESIUM OXIDE, SALICYLAMIDE. Patient was hospitalized. Patient recovered.
Physician from JAPAN reported IRINOTECAN problem on Aug 10, 2006. Male patient, 67 years of age, weighting 138.5 lb, was diagnosed with colon cancer and was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: cell marker increased, interstitial lung disease, pneumonia fungal. IRINOTECAN dosage: unknown. During the same period patient was treated with TEGAFUR, NORVASC. Patient recovered.
IRINOTECAN problem was reported by a Consumer or non-health professional from UNITED STATES on Sept 07, 2006. Male patient, weighting 200.0 lb, was diagnosed with glioblastoma multiforme and was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: abdominal pain, diarrhoea. IRINOTECAN dosage: 325 MG/M2 DAY 1, 8, 22, 29 IV. During the same period patient was treated with TEMODAR, DILANTIN, LEXAPRO, PHRENILIN, OXYCODONE, DEXAMETHASONE, KEPPRA. Patient was hospitalized. Patient recovered.
Health Professional from JAPAN reported IRINOTECAN problem on Aug 25, 2006. Female patient, 71 years of age, was diagnosed with ovarian cancer and was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: myelodysplastic syndrome. IRINOTECAN dosage: unknown. Patient recovered.
IRINOTECAN problem was reported by a Health Professional from UNITED STATES on Sept 13, 2006. Male patient, 69 years of age, weighting 141.0 lb, was diagnosed with neoplasm malignant and was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: dysphasia, malignant neoplasm progression, performance status decreased, pneumonia aspiration. IRINOTECAN dosage: 50 MG/M2 D1,8,22,29 Q 6WKS IV. During the same period patient was treated with CISPLATIN. Patient was hospitalized. Patient recovered.
Physician from JAPAN reported IRINOTECAN problem on Aug 25, 2006. Male patient, 74 years of age, weighting 126.1 lb, was diagnosed with pleural mesothelioma malignant and was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: interstitial lung disease, lymphocyte stimulation test positive, pyrexia, respiratory failure. IRINOTECAN dosage: 60 MG (1 IN 7 D), INTRAVENOUS. During the same period patient was treated with METHOTREXATE, DOXORUBICIN. Patient recovered.
IRINOTECAN problem was reported by a Physician from JAPAN on Sept 01, 2006. Female patient, 61 years of age, weighting 97.00 lb, was diagnosed with gastric cancer and was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: hyperkalaemia, ill-defined disorder, leukopenia, malignant neoplasm progression, metastases to peritoneum, neutropenia. IRINOTECAN dosage: 66.7 MG/M2, INTRAVENOUS. During the same period patient was treated with CISPLATIN. Patient recovered.
Health Professional from FRANCE reported IRINOTECAN problem on Dec 24, 1991. Female patient, 53 years of age, was diagnosed with laryngeal cancer and was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: diarrhoea, septic shock. IRINOTECAN dosage: unknown. During the same period patient was treated with DICLOFENAC, MORPHINE. Patient died on 12/23/1991.
IRINOTECAN problem was reported by a Physician from UNITED STATES on Sept 25, 2006. Female patient, 65 years of age, weighting 189.0 lb, was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: clostridial infection, febrile neutropenia, neutrophil count increased, rebound effect, white blood cell count increased. IRINOTECAN dosage: 150 MG/M2 Q3W IV. During the same period patient was treated with OXALIPLATIN, NEULASTA, AVANDIA, GLIPIZIDE ER, ACIPHEX, ENALAPRIL MALEATE, BUSPIRONE, FLUOXETINE. Patient was hospitalized. Patient recovered.
Health Professional from FRANCE reported IRINOTECAN problem on Nov 26, 1992. Male patient, 68 years of age, was diagnosed with colon cancer and was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: no adverse effect. IRINOTECAN dosage: 612 MG (1 IN 3 WK), INTRAVENOUS. During the same period patient was treated with CYPROHEPTADINE, VITAMINS WITH MINERALS, MORPHINE, PHLOROGLUCINOL, THEODRENALINE. Patient recovered.
IRINOTECAN problem was reported by a Physician from FRANCE on Sept 12, 2006. Female patient, 54 years of age, weighting 130.1 lb, was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: blood lactate dehydrogenase increased, renal failure acute. IRINOTECAN dosage: 150 MG (150 MG,1 IN 1 D), INTRAVENOUS. During the same period patient was treated with LEUCOVORIN CALCIUM, ONDANSETRON, AVASTIN, ATROPINE SULPHATE, FLUOROURACIL. Patient was hospitalized. Patient died.
Health Professional from JAPAN reported IRINOTECAN problem on Sept 11, 2006. Female patient, 71 years of age, was diagnosed with ovarian cancer and was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: cellulitis, marrow hyperplasia, myelodysplastic syndrome, rectal neoplasm, refractory anaemia with an excess of blasts, thrombocytopenia, vaginal haemorrhage. IRINOTECAN dosage: unknown. Patient recovered.
IRINOTECAN problem was reported by a Consumer or non-health professional from UNITED STATES on Sept 27, 2006. Male patient, weighting 200.0 lb, was diagnosed with glioblastoma multiforme and was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: aspartate aminotransferase increased, blood alkaline phosphatase increased, diarrhoea, haemoglobin decreased, hyponatraemia, neutropenia. IRINOTECAN dosage: 325 MG /M2 DAY 1, 8, 22, 29 IV. During the same period patient was treated with TEMODAR, DILANTIN, LEXAPRO, PHREMILIN, OXYCODONE, DEXAMETHASONE, KEPPRA, ZANTAC. Patient was hospitalized. Patient recovered.
Physician from JAPAN reported IRINOTECAN problem on Sept 14, 2006. Female patient, 61 years of age, weighting 97.00 lb, was diagnosed with gastric cancer and was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: hyperkalaemia, leukopenia, malignant neoplasm progression, neutropenia, peritoneal carcinoma. IRINOTECAN dosage: 66.7 MG/M2, INTRAVENOUS. During the same period patient was treated with CISPLATIN. Patient recovered.
IRINOTECAN problem was reported by a Physician from JAPAN on Sept 13, 2006. Female patient, 67 years of age, weighting 81.57 lb, was diagnosed with ovarian cancer and was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: anorexia, bone marrow failure, condition aggravated, infection, interstitial lung disease, malaise, malnutrition, metastases to spleen. IRINOTECAN dosage: unknown. During the same period patient was treated with NEUPOGEN, ETOPOSIDE, TAXOTERE. Patient was hospitalized. Patient died on 03/03/2005.
Physician from JAPAN reported IRINOTECAN problem on Sept 13, 2006. Male patient, 57 years of age, was diagnosed with lung adenocarcinoma and was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: blood cholesterol increased, glomerulonephritis membranous, nephrotic syndrome, pleural effusion. IRINOTECAN dosage: unknown. During the same period patient was treated with PACLITAXEL, IRESSA. Patient was hospitalized. Patient recovered.
IRINOTECAN problem was reported by a Health Professional from UNITED STATES on Nov 30, 2005. Female patient, 66 years of age, was diagnosed with colorectal cancer metastatic, diarrhoea, arthralgia, pain in extremity, nausea and was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: nausea, vomiting. IRINOTECAN dosage: unknown. During the same period patient was treated with IMODIUM, DARVOCET, KYTRIL. Patient was hospitalized. Patient recovered.
Physician from ITALY reported IRINOTECAN problem on Sept 20, 2006. Female patient, 66 years of age, weighting 134.5 lb, was diagnosed with non-small cell lung cancer and was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: asthenia, confusional state, dyspnoea, metastases to bone, metastases to liver, neuropathy, neurotoxicity, neutrophil percentage increased, pericardial effusion. IRINOTECAN dosage: 90 MG (D1, D8, D15, D22 EVERY SIX WEEKS), INTRAVENOUS. During the same period patient was treated with DOCETAXEL, ALLOPURINOL, CALCIUM, OMEPRAZEN, DELTACORTENE, TRANEX, AMINOMAL ELISIR. Patient was hospitalized. Patient recovered.
IRINOTECAN problem was reported by a Consumer or non-health professional from UNITED STATES on Oct 10, 2006. Male patient, weighting 161.6 lb, was diagnosed with glioblastoma multiforme and was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: loss of consciousness, pneumocystis jiroveci pneumonia, pyrexia. IRINOTECAN dosage: 125MG/M2 DAY 1, 8, 22, 29 IV. During the same period patient was treated with TEMODAR, DECADRON, ZANTAC, FLORINEF. Patient was hospitalized. Patient recovered.
Physician from UNITED STATES reported IRINOTECAN problem on Sept 25, 2006. Male patient, 53 years of age, weighting 167.0 lb, was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: acute respiratory distress syndrome. IRINOTECAN dosage: 150 MG/M1 (1 IN 3 WK), INTRAVENOUS. During the same period patient was treated with OXALIPLATIN, NEULASTA, DEXAMETHASONE, ONDANSETRON, LORTAB, PROMETHAZINE. Patient died on 06/28/2006.
IRINOTECAN problem was reported by a Physician from JAPAN on Sept 27, 2006. Female patient, 67 years of age, was diagnosed with colon cancer metastatic and was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: blood bilirubin increased, blood creatinine increased, condition aggravated, diarrhoea, dyspnoea, haemoglobin decreased, hepatorenal failure, hyperthermia. IRINOTECAN dosage: 160 MG, INTRAVENOUS (SEE IMAGE). Patient was hospitalized. Patient died on 05/18/2004.
Health Professional from UNITED STATES reported IRINOTECAN problem on Oct 13, 2006. Male patient, weighting 211.4 lb, was diagnosed with oligodendroglioma and was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: activated partial thromboplastin time abnormal, deep vein thrombosis, embolism, prothrombin time abnormal. IRINOTECAN dosage: 274MG IV (DAY 1,8,22 AND 29). During the same period patient was treated with BEVACIZUMAB, KEPPRA, AMBIEN, FLOMAX, SENOKOT. Patient recovered.
IRINOTECAN problem was reported by a Consumer or non-health professional from UNITED STATES on Sept 29, 2006. Male patient, weighting 240.0 lb, was diagnosed with colon cancer and was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: fatigue, haemoglobin decreased, insomnia, red blood cell count decreased, unevaluable event. IRINOTECAN dosage: 150 MG (150 MG). During the same period patient was treated with ATROPINE, ALLOPURINOL, ASPIRIN, PLAVIX, TRIAMTERENE, SIMVASTATIN, INSULIN. Patient recovered.
Health Professional from UNITED STATES reported IRINOTECAN problem on Oct 18, 2006. Female patient, weighting 177.3 lb, was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: abdominal pain upper, anorexia, constipation, cytomegalovirus infection, nausea, vomiting. IRINOTECAN dosage: unknown. During the same period patient was treated with CELEBREX, OXYCONTIN, COMPAZINE, KYTRIL, SENNA, COLACE, REGLAN. Patient was hospitalized. Patient recovered.
IRINOTECAN problem was reported by a Health Professional from UNITED STATES on Oct 18, 2006. Male patient, weighting 201.0 lb, was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: small intestinal obstruction. IRINOTECAN dosage: unknown. During the same period patient was treated with CELEBREX, EFFEXOR, PROTONIX, ULTRAM, ZOFRAN. Patient was hospitalized. Patient recovered.
Health Professional from UNITED STATES reported IRINOTECAN problem on Oct 19, 2006. Male patient, weighting 162.0 lb, was diagnosed with glioblastoma multiforme and was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: convulsion, hemiparesis. IRINOTECAN dosage: 644 MG IV (DAY 1, 8, 22 AND 29). During the same period patient was treated with BEVACIZUMAB, DILANTIN, PROTONIX, GLUCOPHAGE. Patient was hospitalized. Patient recovered.
IRINOTECAN problem was reported by a Physician from JAPAN on Oct 04, 2006. Female patient, 56 years of age, was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: diarrhoea, inappropriate antidiuretic hormone secretion, loss of consciousness, vomiting. IRINOTECAN dosage: unknown. During the same period patient was treated with CISPLATIN. Patient was hospitalized. Patient recovered.
Health Professional from JAPAN reported IRINOTECAN problem on May 19, 1999. Male patient, 69 years of age, was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: condition aggravated, contraindication to medical treatment, depressed level of consciousness, grand mal convulsion, hepatic failure, hypokalaemia, leukopenia, malignant neoplasm progression, metastases to liver. IRINOTECAN dosage: 100 MG/M*2, INTRAVENOUS. During the same period patient was treated with AMINO ACIDS, CEFOZOPRAN HYDROCHLORIDE, CLINDAMYCIN PHOSPHATE, HANGE, LENORGRASTIM, METOCLOPRAMIDE, PHENYTOIN, VALPROATE. Patient died on 04/04/1999.
IRINOTECAN problem was reported by a Health Professional from UNITED STATES on Oct 23, 2006. Male patient, 73 years of age, weighting 146.2 lb, was diagnosed with non-small cell lung cancer and was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: dehydration, diarrhoea, neutropenia. IRINOTECAN dosage: 700 MG Q 3 WKS IV. Patient was hospitalized. Patient recovered.
Health Professional from FRANCE reported IRINOTECAN problem on Oct 11, 2006. Female patient, 33 years of age, was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: cytolytic hepatitis, hyperthermia, influenza like illness. IRINOTECAN dosage: 320 MG, INTRAVENOUS. During the same period patient was treated with KYTRIL, FLUOROURACIL, GRANISETRON HYDROCHLORIDE, LEUCOVORIN CALCIUM. Patient was hospitalized. Patient recovered.
IRINOTECAN problem was reported by a Consumer or non-health professional from UNITED STATES on Oct 27, 2006. Female patient, weighting 116.4 lb, was diagnosed with glioblastoma multiforme and was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: glioblastoma multiforme, haematocrit decreased, haemoglobin abnormal, postoperative abscess, pyrexia. IRINOTECAN dosage: 325MG/M2 DAY 1, 8, 22, 29 IV. During the same period patient was treated with TEMODAR, DILANTIN, NEXIUM, DEXAMETHASONE, SENOKOT, ENDOCET. Patient was hospitalized. Patient recovered.
Health Professional from JAPAN reported IRINOTECAN problem on Oct 16, 2006. Male patient, 64 years of age, was diagnosed with ill-defined disorder and was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: acute respiratory failure, interstitial lung disease, leukopenia, neutropenia. IRINOTECAN dosage: (100 MG), INTRAVENOUS. During the same period patient was treated with NEDAPLATIN. Patient recovered.
IRINOTECAN problem was reported by a Health Professional from UNITED STATES on Nov 03, 2006. Male patient, 63 years of age, weighting 173.0 lb, was diagnosed with colon cancer and was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: abdominal distension, bacteraemia, blood pressure increased, bowel sounds abnormal, catheter related infection, dehydration, faecaloma, intestinal functional disorder, intestinal obstruction. IRINOTECAN dosage: 150MG/M2 Q 2 WKS IV. During the same period patient was treated with CETUXIMAB, FLUOXETINE, ASPIRIN, ZYPREXA, COMPAZINE, SENOKOT, IMODIUM, DOXYCYCLINE. Patient was hospitalized. Patient recovered.
Physician from UNITED STATES reported IRINOTECAN problem on Oct 23, 2006. Male patient, 52 years of age, was diagnosed with colon cancer metastatic and was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: homicide, metabolic encephalopathy, neoplasm, psychotic disorder. IRINOTECAN dosage: unknown. Patient recovered.
IRINOTECAN problem was reported by a Consumer or non-health professional from UNITED STATES on Nov 07, 2006. Male patient, weighting 161.6 lb, was diagnosed with glioblastoma multiforme and was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: anaemia, arrhythmia, cardiac disorder, central nervous system infection, ejection fraction decreased, hypoalbuminaemia, hypotension, immunosuppression, loss of consciousness. IRINOTECAN dosage: 125MG/M2 DAY 1, 8, 22, 29 IV. During the same period patient was treated with TEMODAR, DECADRON, ZANTAC, FLORINEF. Patient was hospitalized. Patient recovered.
Consumer or non-health professional from UNITED STATES reported IRINOTECAN problem on Nov 07, 2006. Female patient, weighting 127.2 lb, was diagnosed with glioblastoma multiforme and was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: collapse of lung, confusional state, haematotoxicity, haemoglobin abnormal, hyperglycaemia, hypoalbuminaemia, hypocalcaemia, hypokalaemia, hyponatraemia. IRINOTECAN dosage: 125MG/M2 DAY 1, 8, 22, 29 IV. During the same period patient was treated with TEMODAR, METOPROLOL, TIMOLOL MALEATE, DECADRON, ACTONEL, PRILOSEC, VALTREX, DIFLUCAN. Patient was hospitalized. Patient recovered.
IRINOTECAN problem was reported by a Physician from JAPAN on Oct 24, 2006. Female patient, 80 years of age, was diagnosed with rectal cancer recurrent and was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: condition aggravated, disseminated intravascular coagulation, pancytopenia, pneumonia, respiratory disorder, staphylococcal infection. IRINOTECAN dosage: 140 MG (1 IN 1 WK), INTRAVENOUS. During the same period patient was treated with LEUCOVORIN CALCIUM. Patient died on 11/15/2005.
Consumer or non-health professional from FRANCE reported IRINOTECAN problem on Feb 04, 1998. Male patient, 44 years of age, was diagnosed with metastasis, colorectal cancer and was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: abdominal pain, asthenia, malaise, pain in jaw, pulmonary embolism. IRINOTECAN dosage: unknown. During the same period patient was treated with FLUOROURACIL, FOLINIC ACID. Patient died on 01/19/1998.
IRINOTECAN problem was reported by a Health Professional from HUNGARY on Nov 15, 2001. Male patient, 70 years of age, was diagnosed with gastric cancer and was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: asthenia, cholecystitis acute, cholelithiasis, nausea, pyrexia. IRINOTECAN dosage: 110 MG, CYCLICALLY, INTRAVENOUS. During the same period patient was treated with LEUCOVORIN CALCIUM, FLUOROURACIL, ENSURE PLUS, FERROGRAD, VALIUM. Patient was hospitalized. Patient recovered.
Consumer or non-health professional from FRANCE reported IRINOTECAN problem on Oct 03, 1996. Male patient, 61 years of age, was diagnosed with colorectal cancer metastatic and was treated with IRINOTECAN. After drug was administered, patient experienced the following problems/side effects: activated partial thromboplastin time prolonged, anaemia, blood creatinine decreased, blood potassium decreased, blood sodium decreased, international normalised ratio decreased, phlebitis, red blood cell sedimentation rate increased. IRINOTECAN dosage: 150 MG/M*2 (CYCLICALLY), INTRAVENOUS. Patient was hospitalized. Patient recovered.
Showing 1-75 of 266 Next >
This
drug has an active FDA Safety Alert